Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline

(Abstracted from J Clin Oncol 2016;34:3460–3473) Treatment with primary cytoreductive surgery (PCS) followed by neoadjuvant chemotherapy (NACT) has been the standard of care for women with stage IIIC or IV epithelial ovarian cancer (EOC). However, data from 2 recent randomized controlled trials suggest that PCS can be a first option in these women.